UDIO BOLESNIKA на Английском - Английский перевод

• proportion of patients
• proportions of patients
• rate of patients

Примеры использования Udio bolesnika на Хорватском языке и их переводы на Английский язык

Udio bolesnika u GINA koracima 4 i 5c.
Proportions of patients in GINA steps 4 and 5c.

Primijećen je i kumulativan učinak na transaminaze udio bolesnika s odstupanjima vrijednosti ALT-a/AST-a stupnja 1-2 povećava se sa svakim sljedećim ciklusom.
A cumulative effect on transaminases has also been observed the proportion of patients with Grade 1-2 ALT/AST abnormalities increases with successive cycles.

Udio bolesnika koji su postigli ciljni HbA1c< 7.
Proportions of patients achieving HbA1c< 7% targets.

Veličina imunološkog odgovora na cjepivo protiv sezonske gripe i udio bolesnika sa serokonverzijom i serozaštitom bili su u skladu s onima zabilježenima kod populacije zdravih dobrovoljaca.
The magnitude of the immune response to the seasonal influenza vaccine, and proportion of patients with seroconversion and seroprotection were consistent with those observed in healthy volunteer populations.

Jedan udio bolesnika nije podvrgnut nikakvom smanjenju doze, na osnovu individualne procjene koristi i rizika.
A proportion of patients did not undergo any dose reduction, based on an individual benefit-risk assessment.

U svim ispitivanim populacijama veći je udio bolesnika postigao gubitak tjelesne težine ≥5% i >10% uz primjenu liraglutida nego uz placebo(tablice 3- 5).
Across the trial populations, greater proportions of the patients achieved≥5% and>10% weight loss with liraglutide than with placebo(tables 3- 5).

Udio bolesnika koji su doživjeli srčane nuspojave(sve ili samo ozbiljne) nije se povećao tijekom višestrukih ciklusa.
The proportions of patients experiencing cardiac reactions(all or serious) did not increase over multiple courses.

II. dio: U razdoblju ustezanja u ključnom ispitivanju primarna mjera ishoda bila je definirana kao udio bolesnika s relapsom/razbuktavanjem bolesti: nijedan(0%) od bolesnika randomiziranih na Ilaris nije imao razbuktavanje bolesti, u usporedbi s 81% bolesnika randomiziranih na placebo.
Part II: In the withdrawal period of the pivotal study, the primary endpoint was defined as the proportion of patients with a disease relapse/flare: none(0%) of the patients randomised to Ilaris flared, compared with 81% of the patients randomised to placebo.

Slika 1: Udio bolesnika prema kategoriji odgovora s obzirom na napadaje uz brivaracetam i placebo tijekom 12 tjedana u sva tri dvostruko slijepa pivotalna ispitivanja.
Figure 1: Proportion of patients by category of seizure response for brivaracetam and placebo over 12 weeks across all three double-blind pivotal trials.

U ispitivanju na djeci, glavna mjera djelotvornosti bila je udio bolesnika i kojih je broj napadaja bio barem prepolovljen između 8 tjedana prije početak liječenja i 12-tjednog razdoblja kad je korištena stabilna doza.
In the study in children, the main measure of effectiveness was the proportion of patients in whom the number of seizures was at least halved between the 8 weeks before treatment started and the 12-week period when a stable dose was used.

Tablica 6: Udio bolesnika u pojedinim podskupinama u kojih je u 48. tjednu postignuto 50 kopija/ml zajednički podaci ispitivanja MOTIVATE 1 i MOTIVATE 2.
Table 6: Proportion of patients achieving< 50 copies/mL at Week 48 by subgroup pooled Studies MOTIVATE 1 and MOTIVATE 2.

Analizom prema liječenju, isključujući vrijednosti koje su nedostajale, udio bolesnika s HIV RNK< 400 kopija/ml(< 50 kopija/ml) u skupini koja je primala REYATAZ s ritonavirom iznosio je 55%(40%), a u skupini koja je primala lopinavir s ritonavirom 56% 46.
By as-treated analysis, excluding missing values, the proportions of patients with HIV RNA< 400 copies/ml(< 50 copies/ml) in the REYATAZ+ ritonavir arm and the lopinavir+ ritonavir arm were 55%(40%) and 56%(46%).

Slika 2: Udio bolesnika s potvrđenom onesposobljenosti tijekom 24 tjedna ispitivanje DECIDE.
Figure 2: Proportion of patients with 24 week confirmed disability DECIDE study.

Klinički ishodi: udio bolesnika koji zahtijevaju liječenje akutnog napada gihta.
Clinical Outcomes: proportion of patients requiring treatment for a gout flare.

Udio bolesnika kojima je sluznica zacijelila u 26. tjednu bio je značajno veći u skupini koja je primala infliksimab+ AZA(43,9%, p< 0,001) i skupini koja je primala monoterapiju infliksimabom(30,1%, p 0,023) nego u skupini koja je primala monoterapiju AZA 16, 5.
The proportions of patients with mucosal healing at week 26 were significantly greater in the infliximab plus AZA combination(43.9%, p< 0.001) and infliximab monotherapy groups(30.1%, p 0.023) compared to the AZA monotherapy group 16.5.

I u UNITI-1 i UNITI-2, značajno veći udio bolesnika bili su s kliničkim odgovorom i remisijom u skupini liječenoj ustekinumabom u usporedbi s placebom Tablica 3.
In both UNITI-1 and UNITI-2, a significantly greater proportion of patients were in clinical response and remission in the ustekinumab treated group compared to placebo Table 3.

Udio bolesnika bez znakova virusne aktivnosti u krvi prilikom praćenja iznosio je 32% s lijekom Pegasys i 22% s lamivudinom u HBeAg-pozitivnih bolesnika te 43% s lijekom Pegasys te 29% s lamivudinom kod HBeAg-negativnih bolesnika..
The proportions of patients with no signs of viral activity in their blood at follow-up were 32% with Pegasys and 22% with lamivudine in the HBeAg-positive patients, and 43% with Pegasys and 29% with lamivudine in the HBeAg-negative patients..

U oba HCV ispitivanja, značajno veći udio bolesnika koji je liječen eltrombopagom(n=201, 21%), postigao je SVR u odnosu na bolesnike koji su primali placebo(n=65, 13%) vidjeti tablicu 7.
In both HCV studies, a significantly greater proportion of patients treated with eltrombopag(n=201, 21%) achieved SVR compared to those treated with placebo(n=65, 13%) see Table 7.

Tablica 2: Udio bolesnika s klinički relevantnim oporavkom oštrine vida nakon 6 mjeseci od početne vrijednosti.
Table 2: Proportion of patients with clinically relevant recovery of VA after 6 months from baseline.

Glavna mjera djelotvornosti bila je udio bolesnika čija se slezena smanjila za najmanje 35%, mjereno nakon šest mjeseci u prvom ispitivanju i nakon godine dana u drugom ispitivanju.
The main measure of effectiveness was the proportion of patients whose spleen had reduced in size by at least 35%, measured after six months in the first study and after one year in the second study.

Iako je udio bolesnika s poremećajem govora bio manji kod otpusta, razlika nije bila statistiki znaajna.
Although the rate of patients with speech disorders was lower at discharge, the difference was not statistically significant.

U 12. je tjednu značajno veći udio bolesnika u ispitivanju HS-II doživio klinički značajno smanjenje kožne boli uzrokovane gnojnim hidradenitisom vidjeti Tablicu 14.
At Week 12, a significantly higher proportion of patients in Study HS-II experienced a clinically relevant decrease in HS-related skin pain see Table 14.

Tablica 6 Udio bolesnika koji su postigli< 400 kopija/ml i< 50 kopija/ml u 48. tjednu po podskupinama objedinjeni podaci iz TORO 1 i TORO 2, ITT.
Table 6 Proportion of Patients achieving< 400 copies/ml and< 50 copies/ml at Week 48 by subgroup pooled TORO 1 and TORO 2, ITT.

U obje terapijske skupine je udio bolesnika u kojih se javila febrilna neutropenija bio najveći tijekom prvog ciklusa liječenja, nakon čega se stalno smanjivao.
In both treatment groups, the proportion of patients experiencing febrile neutropenia was highest in the first cycle of therapy and declined steadily thereafter.

Općenito je udio bolesnika koji su imali neku reakciju povezanu s infuzijom bio veći nakon prve infuzije nego nakon druge infuzije u bilo kojem ciklusu liječenja.
In general, the proportion of patients experiencing any infusion reaction was higher following the first infusion than following the second infusion of any treatment course.

A Stopa potpunog nestanka definirana je kao udio bolesnika s nijednom(nula) klinički vidljivom lezijom aktiničke keratoze u liječenom području. b Stopa djelomičnog nestanka definirana je kao postotak bolesnika kod kojih se povuklo 75% ili više od.
A Complete clearance rate was defined as the proportion of patients with no(zero) clinically visible actinic keratosis lesions in the treatment area. b Partial clearance rate was defined as the percentage of patients in whom 75% or more of the number of baseline.

Tablica 3 Udio bolesnika s početnom vrijednosti sUA> 5, 0 mg/dl koji su postigli ciljne razine mokraćne kiseline u serumu(< 5 mg/dl) uz liječenje lijekom Zurampic u kombinaciji s febuksostatom.
Table 3 Proportion of patients with baseline sUA≥5.0 mg/dLwho achieve target serum uric acid levels(< 5 mg/dL) with Zurampic in combination with febuxostat.

U ispitivanjima s fiksnom dozom, udio bolesnika koji su prijavili poboljšanje svoje erekcije uz terapiju iznosio je 62%(25 mg), 74%(50 mg) i 82%(100 mg), u usporedbi s 25% bolesnika koji su primali placebo.
In the fixed-dose studies, the proportions of patients reporting that treatment improved their erections were 62%(25 mg), 74%(50 mg) and 82%(100 mg), compared with 25% on placebo.

U 24. tjednu je udio bolesnika s vrijednošću virusne RNK u plazmi manjom od 400 kopija/ml iznosio 60.
At week 24, the proportion of patients with plasma viral RNA below 400 copies/mL was 60.

Za oba cjepiva udio bolesnika s dostatnom količinom protutijela na tri virusa iznosio je približno 98% ili više.
For both vaccines, the proportion of patients with sufficient amount of antibodies against the three viruses was around 98% or higher.